Use of Bone Scintigraphy, CT and MRI in Breast Cancer

University of Aarhus180 enrolled

Overview

A new imaging modality combining CT and tomographic bone scintigraphy (SPECT/CT) has enabled the combination of functional and anatomical imaging. Its use in cancer patients has not yet been evaluated or validated against a relative gold stand or clinical follow up. The purposes of this study are: 1: to validate the use of conventional planar bone scintigraphy and SPECT combined with low-dose or diagnostic CT and compare this to 3 Tesla MRI and clinical follow up. 2: to compare the specificity of low-dose and diagnostic CT, respectively, combined with bone SPECT. 3: to construct an algorithm for optimal evaluation of disease dissemination in breast cancer patients

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Breast Neoplasms

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological verified breast cancer * Age 18-80 years * Investigation for metastases using imaging modality/modalities planned * Written consent to participate in trial Exclusion Criteria: * Overweight limiting the use of MRI * Metal parts in body * Claustrophobia * Allergy to contrast agents used in trial * Pregnancy

Locations (1)

Aarhus University Hospital

Aarhus, Denmark

RECRUITING

Central Contacts

Anni Eskild-Jensen, MD, PhD, DMSci

CONTACT

+45 8949 2251 aej@ki.au.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.